JTCS KCI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lai, V. K.
Right arrow Articles by Galiñanes, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lai, V. K.
Right arrow Articles by Galiñanes, M.
Related Collections
Right arrow Cardiac - physiology
Right arrow Molecular biology
Right arrow Myocardial protection

J Thorac Cardiovasc Surg 2009;138:1400-1408
© 2009 The American Association for Thoracic Surgery


Evolving Technology/Basic Science

Bone marrow cell–induced protection of the human myocardium: Characterization and mechanism of action

Vien Khach Lai, MD, José Linares-Palomino, MD, PhD, Bernardo Nadal-Ginard, MD, PhD, Manuel Galiñanes, MD, PhD, FRCS*

Cardiac Surgery Unit, Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom

Received for publication March 17, 2009; revisions received June 8, 2009; accepted for publication July 6, 2009.

* Address for reprints: Manuel Galiñanes, MD, PhD, FRCS, Cardiac Surgery Unit, Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital (Clinical Science Wing), LE3 9QP Leicester, United Kingdom. (Email: mg50{at}le.ac.uk).

Objectives: The mechanism of the putative beneficial effect of myocardial transplantation of bone marrow cells remains unclear. We studied the protective properties of bone marrow cells on the human myocardium and investigated the underlying mechanism.

Methods: Bone marrow cells and the right atrial appendage were obtained from patients undergoing elective cardiac surgery. Myocardial slices were subjected to 90 minutes of simulated ischemia/120 minutes of reoxygenation at 37°C following various protocols. Tissue injury was assessed by creatine kinase released into the media during the reoxygenation period, and myocardial necrosis and apoptosis were determined by propidium iodide and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (percent of aerobic control).

Results: Autologous unfractionated bone marrow cells significantly reduced myocardial injury. Maximal protection was obtained with 5 x 106 autologous cells (~1.5 x 105 cells/mg wet myocardium) that caused a reduction in creatine kinase release and cell death by necrosis and apoptosis of 70% to 80%. Allogenic bone marrow cells were as protective as the autologous cells and their effect was unaffected by prior frozen storage or culturing. Similar myocardial protection was also attained when bone marrow cells were present only before or during ischemia, or during reoxygenation, a benefit that was comparable with that of ischemic preconditioning. Conditioned media by the bone marrow cells was sufficient to induce protection, which was abolished by the selective insulin-like growth factor-1 receptor blocker PQ401.

Conclusions: Bone marrow cells possess potent myocardial protective properties that are triggered by a secreted factor or factors and mediated by insulin-like growth factor-1 receptor. These results have important clinical implications for the therapeutic use of bone marrow cells in ischemic heart disease and for the design of future clinical studies.



Abbreviations and Acronyms BMC = bone marrow cell; CK = creatine kinase; DAPI = 4'6-diamidino-2-phenylindole; ELISA = enzyme-linked immunosorbent assay; IGF = insulin-like growth factor; IGF-1R = insulin-like growth factor-1 receptor; IP = ischemic preconditioning; I/R = ischemia/reoxygenation; KHH = Krebs/Henseleit/Hepes





This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
J. L. Herrmann, A. M. Abarbanell, Y. Wang, B. R. Weil, J. A. Poynter, M. C. Manukyan, and D. R. Meldrum
Transforming Growth Factor-{alpha} Enhances Stem Cell-Mediated Postischemic Myocardial Protection
Ann. Thorac. Surg., November 1, 2011; 92(5): 1719 - 1725.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. M. Ellison, D. Torella, S. Dellegrottaglie, C. Perez-Martinez, A. Perez de Prado, C. Vicinanza, S. Purushothaman, V. Galuppo, C. Iaconetti, C. D. Waring, et al.
Endogenous Cardiac Stem Cell Activation by Insulin-Like Growth Factor-1/Hepatocyte Growth Factor Intracoronary Injection Fosters Survival and Regeneration of the Infarcted Pig Heart
J. Am. Coll. Cardiol., August 23, 2011; 58(9): 977 - 986.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The American Association for Thoracic Surgery.